{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T23:11:15Z","timestamp":1789168275054,"version":"build-2803163510"},"reference-count":30,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T00:00:00Z","timestamp":1616630400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To assess the trends in the prescribing of antiobesity medications and the characteristics of patients recently initiating antiobesity drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>We conducted a population\u2010based cohort study using claims data from commercial health insurances in the United States. Patients initiating an antiobesity drug between January 2004 and December 2018 were included. Trends in the utilization of antiobesity medications were plotted by year, as a proportion of any antiobesity treatment, and as initiation rates per 100\u2009000. Descriptive statistics were used to summarize the characteristics of antiobesity initiators.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>From 2004 to 2018, 626\u2009216 patients started an antiobesity medication (two per 100\u2009000). Phentermine was the most frequently prescribed (50% in 2018). In recent years (2015\u20102018), among 227\u2009692 patients who initiated an antiobesity drug, 51% started phentermine, 19% naltrexone\u2010bupropion, and 13% liraglutide 3.0\u2009mg. Compared to other agents, the use of liraglutide 3.0\u2009mg increased between 2015 and 2018. The average age of initiators was 45\u2009years, 81% of initiators were female, 32% had hypertension, 25% had dyslipidaemia, and 6% had type 2 diabetes. Time on treatment was generally short (mean\u200981\u2009days).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The overall use of antiobesity medications remained low over the past 15\u2009years and phentermine was the preferred antiobesity agent. Although the use of potentially safer antiobesity agents, for example, liraglutide 3.0\u2009mg, has increased in recent years, phentermine remained the most frequently prescribed agent among middle\u2010aged adults with a moderate burden of comorbidities.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.14367","type":"journal-article","created":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T09:41:40Z","timestamp":1614678100000},"page":"1542-1551","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Prescribing trends and clinical characteristics of patients starting antiobesity drugs in the\n                    <scp>United States<\/scp>"],"prefix":"10.1111","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3922-3853","authenticated-orcid":false,"given":"Karine","family":"Suissa","sequence":"first","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine Brigham and Women's Hospital, Harvard Medical School  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Schneeweiss","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine Brigham and Women's Hospital, Harvard Medical School  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Wook","family":"Kim","sequence":"additional","affiliation":[{"name":"School of Medicine Boston University  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8809-9898","authenticated-orcid":false,"given":"Elisabetta","family":"Patorno","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine Brigham and Women's Hospital, Harvard Medical School  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,3,25]]},"reference":[{"key":"e_1_2_9_2_1","first-page":"1","article-title":"Prevalence of obesity among adults and youth: United States, 2015\u20102016","volume":"288","author":"Hales CM","year":"2017","journal-title":"NCHS Data Brief"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-9-88"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000437739.71477.ee"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.026567"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.281361"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.4158\/EP161356.ESGL"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2014.169"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1342"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/oby.22581"},{"key":"e_1_2_9_11_1","unstructured":"U.S. Food and Drug Administration.2020. FDA requests the withdrawal of the weight\u2010loss drug Belviq Belviq XR (lorcaserin) from the market.https:\/\/www.fda.gov\/drugs\/drug\u2010safety\u2010and\u2010availability\/fda\u2010requests\u2010withdrawal\u2010weight\u2010loss\u2010drug\u2010belviq\u2010belviq\u2010xr\u2010lorcaserin\u2010market. (Accessed 09 January 2020)."},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.329"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2017.3919"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0069"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39385.347049.80"},{"key":"e_1_2_9_16_1","unstructured":"U.S. Food and Drug Administration.2020. FDA drug safety communication: FDA recommends against the continued use of meridia (sibutramine).https:\/\/www.fda.gov\/drugs\/drug\u2010safety\u2010and\u2010availability\/fda\u2010drug\u2010safety\u2010communication\u2010fda\u2010recommends\u2010against\u2010continued\u2010use\u2010meridia\u2010sibutramine. (Accessed 09 January 2020)."},{"issue":"9","key":"e_1_2_9_17_1","first-page":"525","article-title":"Lorcaserin (Belviq): a selective serotonin 5\u2010HT2C agonist in the treatment of obesity","volume":"38","author":"Gustafson A","year":"2013","journal-title":"P & T"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/oby.21533"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1067\/maj.2001.114450"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13672"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/oby.22462"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/cob.12323"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/oby.20309"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2014.10.2817"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1808721"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60205-5"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.orcp.2013.03.003"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.13.1549"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.2014"},{"issue":"5","key":"e_1_2_9_30_1","doi-asserted-by":"crossref","first-page":"373","DOI":"10.7326\/0003-4819-157-5-201209040-00475","article-title":"Force USPST. Screening for and management of obesity in adults: U.S. Preventive Services Task Force recommendation statement","volume":"157","author":"Moyer VA","year":"2012","journal-title":"Ann Intern Med"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2009.175"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.14367","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.14367","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.14367","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T05:37:07Z","timestamp":1761889027000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.14367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,25]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["10.1111\/dom.14367"],"URL":"https:\/\/doi.org\/10.1111\/dom.14367","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/DOM.14367\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14367\/v3\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14367\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14367\/v1\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14367\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14367\/v3\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14367\/v3\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14367\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14367\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14367\/v1\/review2","asserted-by":"object"}]},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,25]]},"assertion":[{"value":"2020-11-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}